These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22027664)

  • 1. [Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia].
    Gavrilova SI; Kalyn IaB; Kolykhalov IV; Roshchina IF; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9):16-22. PubMed ID: 22027664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative analyses of clock drawings in Alzheimer's disease and vascular dementia.
    Kitabayashi Y; Ueda H; Narumoto J; Nakamura K; Kita H; Fukui K
    Psychiatry Clin Neurosci; 2001 Oct; 55(5):485-91. PubMed ID: 11555344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of memantine for elderly patients in the mild stage of Alzheimer's and vascular dementia].
    Bachyns'ka NIu; Rozheliuk IF; Polietaieva KM; Kholin VO
    Lik Sprava; 2013; (7):80-96. PubMed ID: 25509921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
    Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M
    Neurology; 1991 Nov; 41(11):1726-32. PubMed ID: 1944900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type.
    Parnetti L; Gaiti A; Mecocci P; Cadini D; Senin U
    Eur J Clin Pharmacol; 1992; 42(1):89-93. PubMed ID: 1541322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
    Tariot PN; Erb R; Podgorski CA; Cox C; Patel S; Jakimovich L; Irvine C
    Am J Psychiatry; 1998 Jan; 155(1):54-61. PubMed ID: 9433339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the behavioral and psychological symptoms between Alzheimer's disease and vascular dementia: are the different pharmacologic treatment strategies justifiable?
    Kim JM; Lyons D; Shin IS; Yoon JS
    Hum Psychopharmacol; 2003 Apr; 18(3):215-20. PubMed ID: 12672174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hydrogen proton MR spectroscopy of posterior portion cingulate gyrus of patients with Alzheimer's disease: a case control study].
    Wang T; Xiao SF; Li X; Wang Y; Ding B; Ling HW; Chen KM
    Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(1):37-40. PubMed ID: 19489242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people.
    Kwok T; Lee J; Law CB; Pan PC; Yung CY; Choi KC; Lam LC
    Clin Nutr; 2011 Jun; 30(3):297-302. PubMed ID: 21216507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    Passmore AP; Bayer AJ; Steinhagen-Thiessen E
    J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ameliorative Effect of Acetyl L-carnitine in Alzheimer's Disease via Downregulating of Homocysteine Levels in Hyperhomocysteinemia Induced Cognitive Deficit in Mouse Model.
    Verma N; Gupta JK; Varshney KK; Srivastava R
    Drug Metab Lett; 2021; 14(3):219-231. PubMed ID: 34886786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease.
    Pettegrew JW; Klunk WE; Panchalingam K; Kanfer JN; McClure RJ
    Neurobiol Aging; 1995; 16(1):1-4. PubMed ID: 7723928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.